Earth Science Tech, Inc. (OTC: ETST) announced its fiscal first-quarter 2027 financial results, reporting a 57% year-over-year increase in net income to $715,697. The company's revenue reached $9.0 million, a 3% rise from the prior-year period, while gross profit climbed to $6.3 million. Operating cash flow more than doubled to $707,131, and total assets grew to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, reflecting the company's operational efficiency and shareholder value initiatives.
A key highlight of the quarter was the repurchase and retirement of over 3.7 million common shares without incurring additional debt. This move underscores management's commitment to enhancing shareholder value and signals confidence in the company's financial stability. The company's subsidiaries remained profitable, contributing to the robust performance.
Earth Science Tech continues to expand the licensing footprint of its compounding pharmacy operations across the United States. This expansion is part of a broader strategy to build a vertically integrated healthcare platform that combines compounding pharmacy services, telemedicine, and direct-to-patient fulfillment. The company is also evaluating opportunities to broaden its telehealth and pharmacy fulfillment platforms, aiming to capitalize on the growing demand for integrated healthcare solutions.
Management will discuss these results and strategic initiatives at the annual shareholder meeting scheduled for Aug. 31, 2026. Investors will vote on proposals including the cancellation of the company's Series B Preferred Stock, a move that could simplify the capital structure. Additionally, management will provide updates on a potential exchange uplisting, which is intended to improve liquidity and market visibility for the company's shares.
The positive financial performance and strategic actions position Earth Science Tech for continued growth in the health and wellness sector. The company's focus on operational profitability and expansion into high-growth areas, such as telehealth, aligns with industry trends and could enhance its competitive standing. The potential uplisting to a national exchange may attract a broader investor base and increase trading liquidity, potentially benefiting current shareholders.
As the company moves forward, its ability to maintain profitability while scaling operations will be key. The elimination of the Series B Preferred Stock, if approved, would remove a layer of complexity from the capital structure, potentially making the stock more appealing to institutional investors. The company's diversified approach, combining healthcare services with real estate and consumer products, provides a buffer against sector-specific downturns.
Investors and industry observers will be watching the outcomes of the shareholder meeting and the company's progress in expanding its pharmacy licensing and telehealth initiatives. With a solid first-quarter performance and clear strategic direction, Earth Science Tech appears poised to build on its momentum in the coming quarters.
